| Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature GG Dark, SA Hill, VE Prise, GM Tozer, GR Pettit, DJ Chaplin Cancer research 57 (10), 1829-1834, 1997 | 869 | 1997 |
| Differentiation and definition of vascular-targeted therapies DW Siemann, MC Bibby, GG Dark, AP Dicker, FALM Eskens, ... Clinical Cancer Research 11 (2), 416-420, 2005 | 350 | 2005 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 253 | 2018 |
| Pemetrexed combined with Oxaliplatin or carboplatin as first-line treatment in advanced non–small cell lung cancer: a multicenter, randomized, phase II trial GV Scagliotti, C Kortsik, GG Dark, A Price, C Manegold, R Rosell, ... Clinical cancer research 11 (2), 690-696, 2005 | 234 | 2005 |
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis … AR Clamp, EC James, IA McNeish, A Dean, JW Kim, DM O'Donnell, ... The Lancet 394 (10214), 2084-2095, 2019 | 179 | 2019 |
| Surveillance policy for stage I ovarian germ cell tumors. GG Dark, M Bower, ES Newlands, F Paradinas, GJ Rustin Journal of clinical oncology 15 (2), 620-624, 1997 | 167 | 1997 |
| Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program P Taylor, B Castagneto, G Dark, M Marangolo, GV Scagliotti, ... Journal of Thoracic Oncology 3 (7), 764-771, 2008 | 94 | 2008 |
| A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell … R Booton, P Lorigan, H Anderson, S Baka, L Ashcroft, M Nicolson, ... Annals of oncology 17 (7), 1111-1119, 2006 | 89 | 2006 |
| Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national … GG Dark, AH Calvert, R Grimshaw, C Poole, K Swenerton, S Kaye, ... Journal of clinical oncology 23 (9), 1859-1866, 2005 | 74 | 2005 |
| An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a … M Gore, A Hackshaw, WE Brady, RT Penson, R Zaino, WG McCluggage, ... Gynecologic oncology 153 (3), 541-548, 2019 | 70 | 2019 |
| Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer IB Vergote, A Garcia, J Micha, C Pippitt, J Bendell, D Spitz, N Reed, ... Journal of clinical oncology 31 (32), 4060, 2013 | 53 | 2013 |
| Phase II study of vinflunine in malignant pleural mesothelioma DC Talbot, J Margery, G Dabouis, G Dark, H Taylor, H Boussemart, ... Journal of clinical oncology 25 (30), 4751-4756, 2007 | 53 | 2007 |
| Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours H Bourgeois, J Vermorken, G Dark, A Jones, P Fumoleau, R Stupp, ... Cancer chemotherapy and pharmacology 60, 407-413, 2007 | 40 | 2007 |
| Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial … ME Gore, A Hackshaw, WE Brady, RT Penson, RJ Zaino, ... Journal of Clinical Oncology 33 (15_suppl), 5528-5528, 2015 | 38 | 2015 |
| Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory … RD Morgan, IA McNeish, AD Cook, EC James, R Lord, G Dark, ... The Lancet Oncology 22 (2), 277-288, 2021 | 37 | 2021 |
| The on-line medical dictionary G Dark | 36 | 2001 |
| Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. IB Vergote, JP Micha, CH Pippitt Jr, GG Rao, DL Spitz, N Reed, GG Dark, ... Journal of Clinical Oncology 28 (15_suppl), 5013-5013, 2010 | 35 | 2010 |
| Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised … SP Blagden, AD Cook, C Poole, L Howells, IA McNeish, A Dean, JW Kim, ... The Lancet Oncology 21 (7), 969-977, 2020 | 30 | 2020 |
| Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease ARA Razak, L Li, A Bryant, I Diaz-Padilla Cochrane Database of Systematic Reviews, 2011 | 30 | 2011 |
| O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer GV Scagliotti, C Kortsik, C Manegold, G Dark, L Crino, MER O'Brien, ... Lung Cancer, S79, 2003 | 24 | 2003 |
